Objective
Today, development of medicines in Europe is not optimal, most clearly demonstrated by the movement of workplaces to the USA. Outdated development and approval procedures, as well as weak ties between key players within industry, academia and regulatory authorities, also pose major barriers to pharmaceutical progress - to the detriment of patients suffering from illness and disease and the competitive ability of European industry. This contrasts to the fact that modern scientific knowledge and technologies present a realm of opportunities for the drug development process to cultivate new, safe and effective medicines. To reverse this situation, new technological platforms and organizational initiatives are needed for a concerted, continuous pan-European effort, involving all stakeholders in the highly complex drug development process. In this project, compriding a high-level workshop and a further exploitation period, followed by a final report, these aspects will be dealt with and solutions sought in a European context, with representatives from organizations representing all major stakeholders of the process with emphasis on biotech SME's. To secure that the conclusions drawn at the workshop will be disseminated and further exploited towards an operational level, there is the post-workshop activity, limited in time, with an "Exploitation Secretary/Platform Ambassador".
Call for proposal
FP6-2003-LIFESCIHEALTH-I
See other projects for this call
Funding Scheme
SSA - Specific Support ActionCoordinator
1136 STOCKHOLM
Sweden